Cetuximab News and Research

RSS
Cetuximab is an investigational IgG1 monoclonal antibody designed to target and block the Epidermal Growth Factor Receptor (EGFR), which is expressed on the surface of certain cancer cells in multiple tumor types. Cetuximab is designed to bind to EGFR and prevent natural ligands called growth factors from binding to the receptor and inducing phosphorylation, i.e., activation of signaling to the tumor. The most common drug-related adverse events reported in clinical trials of cetuximab have been an acne-like rash and asthenia. Severe allergic reactions may occur in a small percentage of patients.
TAILOR study shows treatment with Erbitux plus FOLFOX improves survival in RAS wild-type mCRC patients

TAILOR study shows treatment with Erbitux plus FOLFOX improves survival in RAS wild-type mCRC patients

Pembrolizumab drug shows significant clinical responses in metastatic head and neck cancer patients

Pembrolizumab drug shows significant clinical responses in metastatic head and neck cancer patients

New research solves mystery of why cetuximab drug proved futile for many colorectal cancer patients

New research solves mystery of why cetuximab drug proved futile for many colorectal cancer patients

Adjuvant Chemotherapy Colon Cancer Trials Should ‘Stratify By MSI, KRAS, BRAF’

Adjuvant Chemotherapy Colon Cancer Trials Should ‘Stratify By MSI, KRAS, BRAF’

Study reveals why colorectal cancer still returns in some patients after treatment

Study reveals why colorectal cancer still returns in some patients after treatment

Landmark 'basket study' shows efficacy of vemurafenib in multiple nonmelanoma BRAFV600-mutated cancers

Landmark 'basket study' shows efficacy of vemurafenib in multiple nonmelanoma BRAFV600-mutated cancers

TNK Therapeutics acquires multiple preclinical and clinical stage CAR-T immunotherapy programs

TNK Therapeutics acquires multiple preclinical and clinical stage CAR-T immunotherapy programs

Scientists successfully test new tumor diagnosis method

Scientists successfully test new tumor diagnosis method

Array Biopharma reports strong fourth quarter and full year 2015 financial results

Array Biopharma reports strong fourth quarter and full year 2015 financial results

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Phase 3 study shows Vectibix meets primary endpoint in patients with chemorefractory wild-type KRAS mCRC

Stony Brook University, CadheRx Therapeutics sign licensing agreement for anti-cancer technology

Stony Brook University, CadheRx Therapeutics sign licensing agreement for anti-cancer technology

SQUIRE phase III study shows necitumumab improves median overall survival in squamous NSCLC patients

SQUIRE phase III study shows necitumumab improves median overall survival in squamous NSCLC patients

Pembrolizumab (Keytruda) effective in patients with recurrent or metastatic head and neck cancer

Pembrolizumab (Keytruda) effective in patients with recurrent or metastatic head and neck cancer

Study quantifies different mutational profiles of tumour cell clusters in patients with bowel cancer

Study quantifies different mutational profiles of tumour cell clusters in patients with bowel cancer

Mixture of two anti-EGFR antibodies clinically active in treatment-resistant colorectal cancer

Mixture of two anti-EGFR antibodies clinically active in treatment-resistant colorectal cancer

Roche announces FDA approval of cobas KRAS Mutation Test for diagnostic use

Roche announces FDA approval of cobas KRAS Mutation Test for diagnostic use

Researchers identify molecular switch for protein that causes HER2-positive breast cancer

Researchers identify molecular switch for protein that causes HER2-positive breast cancer

Amgen's Vectibix (panitumumab) receives EC approval for treatment patients with WT RAS mCRC

Amgen's Vectibix (panitumumab) receives EC approval for treatment patients with WT RAS mCRC

MD Anderson awarded more than $22 million in research grants from CPRIT

MD Anderson awarded more than $22 million in research grants from CPRIT

Novel cancer immunotherapy for dogs could benefit humans as well

Novel cancer immunotherapy for dogs could benefit humans as well